Who is affected and how:

• Newborn infants and families: The primary beneficiaries are newborns (≤21 days) at risk for congenital CMV and their families. Earlier testing can identify infants who may need monitoring or early interventions (for example, for hearing loss or developmental issues), potentially improving long‑term outcomes. Families may receive earlier information and referrals for follow‑up care.

• Hospitals, birthing centers, and clinical providers: Facilities that deliver newborn care will need to integrate testing protocols consistent with State standards, collect and report results, and provide counseling and referrals. This may require training, updated clinical workflows, and coordination with laboratories and public health authorities.

• State public health agencies: States must develop and adopt testing and reporting standards, or rely on the federal advisory committee's standards after a two‑year period. States will also be eligible for federal grants to build capacity, data systems, and public education programs.

• Public health laboratories and diagnostic services: Labs may need to expand or modify capacity to process newborn cCMV tests, adopt validated assays, and participate in data reporting and quality assurance activities.

• Federal agencies and advisory bodies (HRSA, CDC, NIH, advisory committee): These agencies are authorized to provide grants, technical assistance, surveillance, and research support. The advisory committee will take on added review, approval, and fallback standard‑setting responsibilities.

• Research and surveillance communities: The statute authorizes federal research and surveillance funding, which should support better evidence on cCMV prevalence, diagnostic performance, outcomes, and best practices.

Net effects and implementation considerations:

• Public health benefit: Earlier detection of cCMV could enable timely interventions (monitoring, early hearing evaluation, therapy) and reduce morbidity associated with delayed diagnosis.
• Operational costs: Hospitals, labs, and States may face upfront costs to implement testing programs, modify electronic reporting, and train staff; federal grants are authorized to offset those costs but appropriations are required to realize that support.
• Data and privacy: Expanding newborn testing and data systems raises needs for secure reporting, family notification procedures, and clarity on data use and retention.
• Equity and access: Federal support aims to help States implement programs broadly; success will depend on grant availability, outreach, and ensuring underserved populations have access to testing and follow‑up care.